Coronary, canine, antagonist

Figure 6.3 Effect of two structurally distinct thromboxane A2/prostaglandin endoperoxide receptor antagonists, L636,499 and SQ29,548, on the time to coronary occlusion in the canine model of coronary thrombosis following electrically-induced endothelial injury...

Figure 6.5 Percent change in thromboxane A2 and prostacyclin biosynthesis, measured as excretion of their urinary metabolites, 2,3-dinor-thromboxane (Tx) 82 and 2,3-dinor-6-keto-prostaglandin (PG) respectively, in response to a thromboxane A2/prostaglandin endoperoxide receptor antagonist (L636,499) alone and in combination with a thromboxane synthase inhibitor (U63,557A) in the chronic canine model of coronary thrombosis. (Note that occlusion did not occur in dogs treated with the combination therapy)...

Ashton, J.H., Ogletree, M.L., Taylor, A.L., Fitzgerald, C., Rakejo, S., Campbell, W.B., Buja, L.M. and Willerson, J.T. (1985). A thromboxane receptor antagonist, SQ 29,548, abolishes or attenuates cyclic flow variations in severely narrowed canine coronary arteries. Circulation, 72, (Suppl 111), 111—69... 

---